Of the 48 SPMs, 40 (83%) were diagnosed in patients who were contacted for a timely annual TBSE and an additional 4 (8%) were diagnosed in patients who were contacted because they were overdue for this examination. None of these patients were aware of their melanomas (Figure, groups A and B). Four SPMs (8%) were diagnosed in patients who were not due for TBSEs but who detected a worrisome lesion on themselves (Figure, group C) .
The time lapse between the SPM and the most recent prior melanoma ranged from 3 months to 31 years (mean, 4.4 years) (Table) . The mean Breslow thickness of the invasive SPMs was 0.39 mm. Twenty-seven percent of SPMs were thicker than the most recent prior melanoma (13 of 48); 13% were the same thickness (6 of 48); 50% were thinner (24 of 48); and 10% had unknown prior melanoma thicknesses (5 of 48). Sixty-five percent of SPMs occurred on non-sun-exposed skin, presumably decreasing the ease of patient self-detection for these lesions.
With multivariate regression using stepwise backward elimination, age and gender were found not to predict Breslow thickness, but patient awareness of the lesion was a predictive factor. The melanomas detected by patients (group C, average Breslow thickness, 0.57 mm) were significantly thicker than those detected by the dermatologists during screening examinations (groups A and B, average Breslow thickness, 0.22 mm) (P Ͻ .01).
Comment.
A history of melanoma confers an increased risk for SPMs, often occurring within a few months to 2 years after the primary melanoma is identified. However, some studies have shown significantly longer intervals between the initial and second primaries. 3 The long interval found in our study lends support to the concept of lifelong annual follow-up.
Screening TBSEs performed by physicians during the SCREEN study 4 resulted in an increase in melanoma incidence, proving TBSEs to be an effective screening tool. Brobeil Figure. Second primary melanomas diagnosed during 13-month study period. PT indicates patient. *Kaiser Permanente-initiated appointment for screening total-body skin examination. detected, which correlates with the 90% rate in our study. Given the high number of SPMs diagnosed in our patient population over 13 months, at least annual TBSEs for patients with a history of melanoma seems advisable. Breslow thicknesses of SPMs detected through screening examinations are usually thinner than the initial melanomas, but a substantial minority (up to 30%) are thicker. 3 Similarly, in our study, 50% of SPMs were thinner, while 27% were thicker than the most recent prior melanomas. This suggests that routine TBSEs lead to earlier detection of melanomas, thinner Breslow measurements, and therefore improved overall patient survival.
This study evaluated the effect of screening TBSEs on short-term disease detection rates in a high-risk population but did not address long-term effects on patient outcomes or cost-effectiveness. Incidence of SPM in this study is likely increased due to enhanced screening efforts. 4 The utility of screening TBSEs in a low-risk patient population was not addressed. Furthermore, Kaiser Permanente patients may be more amenable to regular preventive health screenings. For dermatology practices without an EHR, a manual spreadsheet of patients with melanoma could be created to track annual follow-up visits.
In conclusion, this study lends further support to the hypothesis that annual TBSEs for patients with a history of melanoma leads to the detection of asymptomatic disease. Using an EHR to identify high-risk patients who are due or overdue for annual TBSEs leads to earlier detection of second primary melanomas and increases patient survival. 
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